AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.05
+1.50%Margins
Gross margin
83.7%
EBITDA margin
-762.2%
EBIT margin
-898.8%
Net margin
-740.0%
FCF margin
-875.0%
-14.4%
Return on equity
-12.5%
Return on assets
-17.1%
Return on invested capital
0.02x
Asset turnover
-$72.9M
Cash from operations
$9.30
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026